Details for Patent: 12,186,362
Which drugs does patent 12,186,362 protect, and when does it expire?
Patent 12,186,362 protects VASOSTRICT and is included in one NDA.
Summary for Patent: 12,186,362
| Title: | Vasopressin formulations for use in treatment of hypotension |
| Abstract: | Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations. |
| Inventor(s): | Matthew Kenney, Vinayagam Kannan, Sunil Vandse, Suketu Sanghvi |
| Assignee: | PH Health Ltd |
| Application Number: | US17/472,393 |
|
Patent Claim Types: see list of patent claims | Formulation; Compound; Dosage form; |
Drugs Protected by US Patent 12,186,362
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-005 | Apr 21, 2021 | AP | RX | Yes | Yes | 12,186,362 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-003 | Apr 15, 2020 | AP | RX | Yes | Yes | 12,186,362 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ph Health | VASOSTRICT | vasopressin | SOLUTION;INTRAVENOUS | 204485-006 | Apr 12, 2023 | DISCN | Yes | No | 12,186,362 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
